Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
400769
Namespace
PUBCHEM
Namespace Version
None
Pattern
^\d+$

Appears in Networks 1

In-Edges 1

path(MESH:"Multiple Sclerosis, Relapsing-Remitting") negativeCorrelation a(PUBCHEM:400769) View Subject | View Object

Patients with relapsing-remitting multiple sclerosis treated with BG-12 for 24 weeks showed significantly fewer new gadolinium-enhancing lesions, with significantly reduced probability of their evolution to T1-hypointense lesions than patients treated with placebo (Macmanus et al., 2011) PubMed:22020111

Out-Edges 6

a(PUBCHEM:400769) increases act(p(HGNC:NFE2L2)) View Subject | View Object

The greatest FImax was observed with Protandim at 135-fold, followed by bardoxolone methyl at 67-fold, dimethyl fumarate at 55-fold, and sulforaphane at 21-fold PubMed:22020111

a(PUBCHEM:400769) increases act(p(HGNC:NFE2L2)) View Subject | View Object

Bardoxolone methyl appeared to produce a biphasic induction, producing near maximal FI over a range of concentrations from less than 40 nM to 0.4 lM PubMed:22020111

a(PUBCHEM:400769) increases act(p(HGNC:NFE2L2)) View Subject | View Object

When compared contemporaneously in the AREc32-based assay, FImax observed was in the order Protandim > bardoxolone methyl > dimethyl fumarate > sulforaphane. PubMed:22020111

a(PUBCHEM:400769) increases act(p(HGNC:NFE2L2)) View Subject | View Object

While Protandim, bardoxolone methyl, BG-12, and sulforaphane all have been demonstrated to modify gene expression profiles by activation of Nrf2, they have not been compared side by side, in the same cell line, under identical conditions. PubMed:22020111

a(PUBCHEM:400769) increases bp(GO:"glomerular filtration") View Subject | View Object

After 52 weeks, the estimated glomerular filtration rate in the 75 mg/day treatment group had increased by 10.5 ± 1.8 ml/min/1.73 m2 (p < 0.001), representing an increase of about 32% when compared to entry values. PubMed:22020111

a(PUBCHEM:400769) negativeCorrelation path(MESH:"Multiple Sclerosis, Relapsing-Remitting") View Subject | View Object

Patients with relapsing-remitting multiple sclerosis treated with BG-12 for 24 weeks showed significantly fewer new gadolinium-enhancing lesions, with significantly reduced probability of their evolution to T1-hypointense lesions than patients treated with placebo (Macmanus et al., 2011) PubMed:22020111

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.